Sei Investments Co. Trims Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Sei Investments Co. decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 40.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,094 shares of the biopharmaceutical company’s stock after selling 61,632 shares during the quarter. Sei Investments Co.’s holdings in Ultragenyx Pharmaceutical were worth $1,929,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Parallel Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares during the period. Leonteq Securities AG lifted its stake in Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,333 shares during the period. Danske Bank A S purchased a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $39,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $56,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 43.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 751 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Shehnaaz Suliman sold 5,740 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the sale, the director directly owned 27,951 shares in the company, valued at approximately $702,129.12. The trade was a 17.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This trade represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 14,292 shares of company stock valued at $351,644. 5.20% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $25.91 on Monday. The stock has a market capitalization of $2.55 billion, a PE ratio of -4.44 and a beta of 0.35. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $39.89. The company has a fifty day moving average of $27.89 and a two-hundred day moving average of $24.81.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.32. The business had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company’s revenue for the quarter was up 28.5% compared to the same quarter last year. During the same quarter last year, the business earned ($1.17) earnings per share. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RARE. Barclays cut their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Wells Fargo & Company dropped their target price on Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Morgan Stanley boosted their price target on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. Wedbush lowered their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Finally, Guggenheim decreased their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $57.82.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.